β受体拮抗剂在心血管疾病的COPD患者中疗效评估  

The efficacy assessment of β blockers in COPD patients with cardiovascular disease

作　　者：杨燕[1] 任云芬 徐大敏[1] 程德忠[1] 刘继东[1] 程晓伟[1] 王浩凌[1] 李淑梅[1] 刘莹[1] 

机构地区：[1]攀枝花市中心医院呼吸内科,四川攀枝花617000

出　　处：《四川医学》2012年第4期632-633,共2页Sichuan Medical Journal

摘　　要：目的研究β受体拮抗剂在并发心血管疾病的COPD患者中运用。方法将COPD并发心血管疾病患者分为5组,分别是ICS、ICS+LABA+TIO、ICS+LABA+TIO+BB,BB,Placebo组,回顾性分析β受体拮抗剂对肺功能、血氧饱和度、病死率的影响。结果 BB治疗组,与ICS、ICS+LABA+TIO组比较,对FEV1降低不显著,有统计学意义(t=7.069,P<0.05);SpO2无统计学意义(t=3.076,P>0.05);β受体拮抗剂治疗组能有效降低病死率,总病死率降低率为18%左右(t=16.87,P<0.05)。结论β受体拮抗剂不会降低并发心血管疾病的COPD患者的FEV1,能降低其病死率。Objective To study effect of β blockers in patients with COPD and cardiovascular disease.Methods Patients with COPD complicated by cardiovascular disease was divided into five groups： ICS,ICS＋LABA＋TIO,ICS＋LABA＋TIO＋BB,BB,Placebo group,retrospective analysis influence of β blockers on lung function,oxygen saturation and mortality.Results BB treatment group,compared with the ICS,ICS＋LABA＋TIO group,had no significant decrease about FEV1,a statistically significant difference（t=7.069,P0.05）;no significant difference of SpO2（t=3.076,P0.05）;β blockers treatment group could effectively reduce the mortality,overall mortality rate was 18%（t=16.87,P0.05）.Conclusion Concurrent βblockers did not reduce FEV1 in patients with COPD with cardiovascular disease,could reduce the mortality rate.

关 键 词：Β受体拮抗剂 肺功能 慢性阻塞性肺部疾病 

分 类 号：R563.9[医药卫生—呼吸系统]